Evidence map›Paper›PMID 24300178›Full record

ArticlePharmaceutics2012

Tissue engineered human skin equivalents.

Zheng Zhang, Bozena B Michniak-Kohn

Abstract read
In one paragraph

Article in Pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed.

  1. Article
  2. Organ-on-a-chip toxicology.Innovation (Cambridge (Mass.)) · 2026
    Review
  3. Article
  4. Article
  5. Skin-on-chip: Quo vadis?APL bioengineering · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Role of Mitochondrial Dynamics in Skin Homeostasis: An Update.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Efficacy ofCurrent issues in molecular biology · 2024
    Article
  12. Article
  13. Article
  14. Improvement in Facial Wrinkles Using Materials EnhancingCurrent issues in molecular biology · 2024
    Article
  15. Review
  16. Recreating Human Skin In Vitro: Should the Microbiota Be Taken into Account?International journal of molecular sciences · 2024
    Review
  17. Review
  18. International journal of molecular sciences · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zheng ZhangNew Jersey Center for Biomaterials, Rutgers-The State University of New Jersey, Piscataway, NJ 08854, USA. michniak@biology.rutgers.edu.
Bozena B Michniak-Kohn

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human skin not only serves as an important barrier against the penetration of exogenous substances into the body, but also provides a potential avenue for the transport of functional active drugs/reagents/ingredients into the skin (topical delivery) and/or the body (transdermal delivery). In the past three decades, research and development in human skin equivalents have advanced in parallel with those in tissue engineering and regenerative medicine. The human skin equivalents are used commercially as clinical skin substitutes and as models for permeation and toxicity screening. Several academic laboratories have developed their own human skin equivalent models and applied these models for studying skin permeation, corrosivity and irritation, compound toxicity, biochemistry, metabolism and cellular pharmacology. Various aspects of the state of the art of human skin equivalents are reviewed and discussed.

Identifiers

PMID24300178
PMCPMC3834903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.